INNOVFIN – EU FINANCE FOR INNOVATORS

SUPPORTING THE FIGHT AGAINST INFECTIOUS DISEASES

With InnovFin Infectious Diseases, the European Investment Bank funds innovators to develop vaccines, drugs, medical and diagnostic devices, and to research infrastructure at the (pre)clinical development stage.

SOME OF THE INNOVATORS WE FINANCE:

- **€ 15M**
  - Mobidiag
  - to scale-up its mobile diagnostics platform
  - Finland 2016

- **€ 20M**
  - Transgene
  - to develop immunotherapy against infectious diseases
  - France 2015

- **€ 20M**
  - Stat-Dx
  - to further develop its diagnostic device
  - Spain 2017

- **€ 20M**
  - BiondVax
  - to develop a universal flu vaccine
  - Israel 2017

- **€ 20M**
  - Da Volterra
  - to fight anti-microbial resistance and prevent C-diff
  - France 2017

- **€ 20M**
  - AntibioTx
  - to fight multi-drug resistant bacteria
  - Denmark 2017

- **€ 20M**
  - Biocartis
  - for diagnostics solutions in infectious diseases
  - Belgium 2018

InnovFin Infectious Diseases is a financial instrument launched in 2015. It is part of InnovFin – EU Finance for Innovators, a joint initiative by the European Commission and the European Investment Bank Group to help innovative firms of all sizes access finance.

InnovFin falls under Horizon 2020, the EU research and innovation programme for 2014-2020.

www.eib.org/innovfin